Summit Securities Group’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-50
Closed -$472K 716
2020
Q4
$472K Sell
50
-6
-11% -$524 0.04% 358
2020
Q3
$487K Sell
56
-40
-42% -$3.46K 0.05% 231
2020
Q2
$838K Buy
96
+46
+92% +$3.97K 0.1% 168
2020
Q1
$412K Buy
+50
New +$4.46K 0.07% 178
2019
Q2
Sell
-42
Closed -$365K 377
2019
Q1
$365K Buy
+42
New +$3.37K 0.07% 142
2014
Q2
Sell
-44
Closed -$1K 632
2014
Q1
$1K Buy
+44
New +$3.21K ﹤0.01% 369

Other funds holding NVS

Summit Securities Group's NVS Position: Q2 2026 in Review

Summit Securities Group sold out of Novartis (NVS) in Q2 2026, closing a stake of 600 shares — an estimated $91.7K sold.

Summit Securities Group first reported a position in NVS in Q2 2013 and held it in 19 quarters. The position peaked at $5.13M in Q4 2023. 1,620 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Summit Securities Group reported no remaining Novartis position as of Q2 2026 after selling out during the quarter.
  • Summit Securities Group sold 600 Novartis shares in Q2 2026, an estimated $91.7K.
  • Summit Securities Group first reported a position in Novartis in Q2 2013 and held it in 19 quarters.
  • Summit Securities Group's Novartis position peaked at $5.13M in Q4 2023.
  • 1,620 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.